Sun Pharma arm to acquire 12.5% stake in WRS Bioproducts, Australia

Sun Pharmaceuticals Industries announced that one of the wholly owned subsidiaries of the Company has agreed to acquire by way of allotment to it, 428,571 ordinary shares (equivalent to 12.5% fully diluted equity stake) of WRS Bioproducts, Australia, a company that is developing novel technologies to produce and commercialize supplements and nutraceutical ingredients from diverse algae species in Australia. The cost of acquisition is AUD 2 million.

Powered by Capital Market - Live News